These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32112057)

  • 1. Real-world evidence and regulatory drug approval.
    Raphael MJ; Gyawali B; Booth CM
    Nat Rev Clin Oncol; 2020 May; 17(5):271-272. PubMed ID: 32112057
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation and Regulation of Oncology Drug Approval: Finding the Right Balance.
    Lyman GH
    JAMA Oncol; 2016 Jun; 2(6):728-9. PubMed ID: 26939751
    [No Abstract]   [Full Text] [Related]  

  • 3. Big and small strides reported in oncology care.
    Adams KT
    Manag Care; 2015 Mar; 24(3):40-1. PubMed ID: 25939193
    [No Abstract]   [Full Text] [Related]  

  • 4. Response Rate as an Approval End Point in Oncology: Back to the Future.
    Blumenthal GM; Pazdur R
    JAMA Oncol; 2016 Jun; 2(6):780-1. PubMed ID: 26913938
    [No Abstract]   [Full Text] [Related]  

  • 5. Model aims to reduce discrepancy between phase II, phase III trials.
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1554-5, 1556. PubMed ID: 11018083
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 7. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
    Cooper S; Bouvy JC; Baker L; Maignen F; Jonsson P; Clark P; Palmer S; Boysen M; Crabb N
    BMJ; 2020 Jan; 368():l6435. PubMed ID: 31896539
    [No Abstract]   [Full Text] [Related]  

  • 8. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 9. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
    Berger ML; Eck S; Ruberg SJ
    J Clin Oncol; 2010 Jul; 28(20):e343-4; author reply e345. PubMed ID: 20458030
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.
    Berry DA; Hudis CA
    JAMA Oncol; 2015 Oct; 1(7):875-6. PubMed ID: 26181139
    [No Abstract]   [Full Text] [Related]  

  • 11. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 12. Are european cancer patients getting a fair deal?
    McVie JG
    Ann Oncol; 2001 Aug; 12(8):1033-5. PubMed ID: 11583176
    [No Abstract]   [Full Text] [Related]  

  • 13. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
    Mailankody S; Prasad V
    JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
    [No Abstract]   [Full Text] [Related]  

  • 14. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
    Gyawali B; Goldstein DA
    JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 16. Selection bias, phase II trials, and the FDA accelerated approval process.
    George SL
    J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncology update.
    Smart M
    Oncol Nurs Forum; 2011 Jul; 38(4):485-6. PubMed ID: 21708539
    [No Abstract]   [Full Text] [Related]  

  • 18. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
    Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
    J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
    Tao D; Schott S; Prasad V
    Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.